Arcutis Biotherapeutics Files Q1 2025 10-Q
Ticker: ARQT · Form: 10-Q · Filed: May 6, 2025 · CIK: 1787306
| Field | Detail |
|---|---|
| Company | Arcutis Biotherapeutics, Inc. (ARQT) |
| Form Type | 10-Q |
| Filed Date | May 6, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, biotech
TL;DR
Arcutis Q1 2025 10-Q is in. Financials and operations updated.
AI Summary
Arcutis Biotherapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates for the first quarter of 2025. Key financial data and disclosures relevant to investors are presented, reflecting the company's ongoing activities in the pharmaceutical sector.
Why It Matters
This filing provides investors with the latest financial health and operational status of Arcutis Biotherapeutics, crucial for understanding its market position and future prospects.
Risk Assessment
Risk Level: medium — As a biopharmaceutical company, Arcutis faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Players & Entities
- Arcutis Biotherapeutics, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of reporting period
- 20250506 (date) — Filing date
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is March 31, 2025.
When was this 10-Q filed with the SEC?
This 10-Q was filed on May 6, 2025.
What is the company's Standard Industrial Classification code?
The company's Standard Industrial Classification code is 2834, Pharmaceutical Preparations.
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
What was the previous company name?
The former company name was Arcutis, Inc., with a date of name change on September 5, 2019.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 6, 2025 regarding Arcutis Biotherapeutics, Inc. (ARQT).